| Document |
Document Title |
|
WO/2021/064191A1 |
In vitro method for detecting, localising and/or quantifying multidrug resistant (MDR) proteins associated with cells, in a sample containing prokaryotic or eukaryotic cells expressing or capable of expressing MDR proteins. The method co...
|
|
WO/2021/066649A1 |
The invention provides method of treatment comprising administering an AQGV peptide, or a functional analogue thereof, to a human subject, the human subject optionally having impaired kidney function, wherein the treatment of administeri...
|
|
WO/2021/059755A1 |
The present invention addresses the problem of providing a technique that enables sympathetic nerve activation. A composition for sympathetic nerve activation, said composition containing one or more peptides selected from the group cons...
|
|
WO/2021/060441A1 |
To provide a high-molecular-weight degradable multi-arm polyethylene glycol derivative that does not cause cell vacuoles. This degradable polyethylene glycol derivative is represented by formula (1). (In the formula, n1 and n2 are each i...
|
|
WO/2021/059840A1 |
[Problem] To provide: a dipeptide having an inhibitory activity against an angiotensin converting enzyme; and others. [Solution] The purpose can be achieved by an angiotensin converting enzyme (ACE) inhibitor comprising at least one dipe...
|
|
WO/2021/060443A1 |
Provided is a high-molecular-weight branched, degradable polyethylene glycol derivative which does not cause cell vacuoles. The branched, degradable polyethylene glycol derivative represented by formula (1) includes an oligopeptide that ...
|
|
WO/2021/060439A1 |
The present invention addresses the problem of providing: a heterobifunctional monodispersed polyethylene glycol having two adjacent monodispersed polyethylene glycol side chains which can sustainedly release a drug upon the decompositio...
|
|
WO/2021/054927A2 |
The present invention describes compositions containing cholesterol-linker-glutathione conjugates for targeting the brain by overcoming barrier entry to the CNS through the blood brain barrier (BBB), including micelle and liposome forms ...
|
|
WO/2021/047558A1 |
Provided is a flanking sequence pair for SspDnaE, SspDnaB, MxeGyrA, MjaTFIIB, PhoVMA, TvoVMA, Gp41-1, Gp41-8, IMPDH-1, or PhoRadA split intein. The flanking sequence pair comprises: flanking sequence a and flanking sequence b, the flanki...
|
|
WO/2021/047524A1 |
The present invention belongs to the field of medical technology and relates to a class of functional small molecules targeting proteolysis pathways, a preparation and an application thereof. Specifically, the present invention relates t...
|
|
WO/2021/047470A1 |
A method for preparing a peptide amide compound represented by formula (N) and an intermediate thereof; the method has mild reaction conditions, simple operations, high reaction yield, high product purity and convenient post-treatment, a...
|
|
WO/2021/045166A1 |
The present disclosure relates to a composition: that contains a polymer compound; that is capable of promoting cell proliferation; that can be used for wound coverings; and that is for culturing or storing cells and tissues. The composi...
|
|
WO/2020/218727A9 |
The present invention relates to peptides isolated from a protein hydrolysate of Tenebrio molitor mealworm and a composition comprising same as an active ingredient for prevention or treatment of liver injury. According to the present in...
|
|
WO/2021/030743A2 |
The present invention provides a compound of formula (I): A-B-C (I), wherein A is a hydrophobic moiety; B is a peptide, wherein the peptide forms a beta-sheet; and C is a hydrophilic targeting ligand, wherein the hydrophilic targeting li...
|
|
WO/2021/020421A1 |
A cell death inhibitor that has as an effective component thereof ascorbic acid, a derivative thereof, a salt thereof, or a solvate thereof and inhibits cell death induced by transient protein expression in plants. The cell death inhibit...
|
|
WO/2021/020585A1 |
To provide a novel heterocyclic compound which has an effect of inducing the degradation of IRAK-M protein and which is expected to be useful for preventing or treating cancer, fibrosis, infectious diseases, etc., and a medicine comprisi...
|
|
WO/2021/018862A1 |
The present invention relates to SS-31 or composition comprising SS-31 for use in the treatment and/or prevention of aneurysm.
|
|
WO/2021/013086A1 |
A compound as represented by general formula (I) or a stereoisomer, a hydrate, a metabolite, a solvate, a pharmaceutically acceptable salt, or a co-crystal thereof, a composition thereof, a preparation method therefor, and an application...
|
|
WO/2021/014229A1 |
The present invention relates to a compound of formula (I) or an enantiomer, to a pharmaceutically acceptable salt or solvate of this compound, or to a mixture thereof, wherein the core A, the substituents Z, Y and R1i are as defined in ...
|
|
WO/2021/013085A1 |
A compound represented by general formula (I) or stereoisomers thereof, a preparation method therefor, and use thereof in medicine, general formula (I) being shown below, and the definition of each substituent being consistent with that ...
|
|
WO/2021/015041A1 |
A retardant for the progression of aging that comprises a peptide Gly-Pro and/or a peptide Glu-Hyp-Gly, a salt thereof or a chemically modified product of the same.
|
|
WO/2021/013684A1 |
The invention relates to detergents or cleaning agents comprising (i) at least one protease which comprises an amino acid sequence which has at least 70% sequence identity to the amino acid sequence given in SEQ ID No. 1 over its entire ...
|
|
WO/2021/013155A1 |
Disclosed are a new glycosyl donor, a preparation method therefor, and an application thereof. Specifically, a glycosyl donor represented by formula (I), a preparation method therefor, and a use of the glycosyl donor represented by formu...
|
|
WO/2021/016182A1 |
Ligand-drug conjugates for targeted melanoma therapies are disclosed herein. A ligand is conjugated to a cytotoxic cancer drug through a cleavage linker. The ligand can bind to an overexpressed receptor on a cancer cell, resulting in sel...
|
|
WO/2021/010482A1 |
The present invention provides a peptide that disrupts the self-aggregation of an AtaA polypeptide or separates a bond between the AtaA polypeptide and another subject. A peptide found by the present inventors has the properties of disru...
|
|
WO/2021/004463A1 |
A method for preparing an antioxidative peptide from a peanut meal by employing a high pressure-assisted enzymatic hydrolysis method, comprising the extraction of heat denatured protein in the peanut meal, high-pressure preprocessing, en...
|
|
WO/2021/003399A1 |
Provided herein are antibodies that specifically bind to human tissue factor (TF), anti-TF antibody-drug conjugates (ADCs), and compositions comprising the antibodies or ADCs. Also provided herein are methods of making and using the anti...
|
|
WO/2021/001244A1 |
The present invention relates to a compound for stabilizing enzymes, the use of said compound for stabilizing an enzyme, a composition comprising said compound, a method of preparing the composition comprising said compound, a detergent ...
|
|
WO/2021/003171A2 |
The present disclosure is directed to peptoids and peptoid multimers that inhibit IL-15 and their use in treating autoimmune/infiammatory diseases.
|
|
WO/2021/002408A1 |
The present invention provides a peptide having a fluoroalkyl group as a side chain. The present invention is a method for manufacturing a fluoroalkyl-group-containing peptide in which a compound represented by general formula (6-2) or (...
|
|
WO/2020/264187A1 |
The present invention generally relates to compounds that are useful for inhibiting one or more trypsin-like S1 serine proteases, HGFA, matriptase, hepsin, KLK5 and/or TMPRSS2 as well as cysteine proteases including trypsin-like cysteine...
|
|
WO/2020/259726A1 |
The present invention relates to cyclen based compounds of general formula (I), wherein X is nitrogen and Y, Z are –CH-, or X, Z are –CH- and Y is nitrogen, or X, Y are –CH- and Z is nitrogen; R1 is independently selected from H; C...
|
|
WO/2020/260309A1 |
The invention provides a compound characterized by formula (1): X1-Thr-Thr-Ala-Arg-X2, wherein cleavage of the compound into a fragment 1 comprising X1 and a fragment 2 comprising X2 generates a detectable signal. The invention further p...
|
|
WO/2020/257745A1 |
Compounds, compositions, and methods are provided that are useful in treating brain diseases by effecting delivery across the blood brain barrier of molecules that otherwise do not (or insignificantly) pass across the blood brain barrier...
|
|
WO/2020/249745A1 |
The present invention relates to cationic micelles, and in particular the compounds capable of forming such cationic micelles for use in cell tracking.
|
|
WO/2020/244224A1 |
Disclosed are a tripeptide propylene oxide derivative or a pharmaceutically acceptable salt thereof, a preparation method therefor and an application thereof. The structure of the tripeptide ethylene oxide derivative is as represented by...
|
|
WO/2020/245772A1 |
The present invention relates to bioactive peptides and to the cosmeceutical compositions comprising them, useful for the prevention and treatment of the signs of skin aging, such as wrinkles, fine lines and loss of firmness and elastici...
|
|
WO/2020/237375A1 |
The disclosure pertains to conformational epitopes in oligomeric tau, antibodies thereto and methods of making and using immunogens and antibodies specific thereto. The antibodies bind activity neutralizing sites in tau. Also provided ar...
|
|
WO/2020/235567A1 |
[Problem] To provide a novel fluorescent probe which can be used in a spray mode, has excellent specificity to sensitivity, also has immediacy, and enables the detection of brain tumor. [Solution] A fluorescent probe for use in the detec...
|
|
WO/2020/236146A1 |
Embodiments of the present disclosure pertain to methods of selecting cyclic peptides that bind to a target by transforming a phage display library with a plurality of nucleic acids into bacterial host cells, where the nucleic acids incl...
|
|
WO/2020/236808A1 |
This disclosure relates to processes for preparing compounds that are useful in the treatment of disease, such as cancer, in mammals. In particular, the invention described herein pertains to processes for preparing compounds capable of ...
|
|
WO/2020/230884A1 |
Provided is a cell culturing scaffold material having excellent adhesiveness for cells. This cell culturing scaffold material contains a peptide-including polyvinyl alcohol derivative that has a polyvinyl alcohol derivative part and a pe...
|
|
WO/2020/229693A1 |
This invention relates pharmaceutical compositions comprising a protein as the active ingredient together with one or more dipeptides as stabilising agents, and optionally an enzyme inhibitor. The compositions are particularly useful for...
|
|
WO/2020/228097A1 |
Provided are a cyclic peptide compound simulating a natural product structure, and a method for preparation thereof. The preparation method is: the compound of formula I, a divalent palladium catalyst, and a silver salt undergoing an int...
|
|
WO/2020/230886A1 |
Provided is a resin film formed of a scaffold material for cell culture, said resin film enabling excellent fixation of cells after seeding and thus contributing to an increase in the cell proliferation rate. The resin film is formed o...
|
|
WO/2020/230885A1 |
Provided is a cell culturing scaffolding material having excellent extensibility of a pseudopodium and an excellent cell-proliferation property. A cell culturing scaffolding material according to the present invention includes a peptid...
|
|
WO/2020/227134A1 |
A method for treating opioid use disorder comprises administering to a subject a pharmaceutical composition comprising a cyclic peptide of Formula I or a pharmaceutically acceptable salt thereof in a pharmaceutically acceptable carrier; ...
|
|
WO/2020/227376A1 |
The present invention generally relates to transplantation rejection. In particular, the present invention provides compositions, kits, assays, and methods of determining if a subject has allograft rejection, or an increased risk of deve...
|
|
WO/2020/227625A1 |
Systems and methods for treatment of squamous cell carcinoma or other cancer utilizing targeting peptides are described. The targeting peptides interact with SCC cells or other cancerous cells to block or interfere with 14-3-3ε heterodi...
|
|
WO/2020/223403A1 |
Embodiments provide for compositions and methods concerning lipid modification of Smacs for use in treating cancer.
|
